Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in Imatinib treated CML patients: A study from India | Zendy

Renu Saxena | Zendy; Sudha Sazawal | Zendy; Sunita Chhikara | Zendy; Kanwaljeet Singh | Zendy; Rekha Chaubey | Zendy; Manoranjan Mahapatra | Zendy; Tulika Seth | Zendy

Open Access

Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in Imatinib treated CML patients: A study from India

Author(s) -

Renu Saxena,

Sudha Sazawal,

Sunita Chhikara,

Kanwaljeet Singh,

Rekha Chaubey,

Manoranjan Mahapatra,

Tulika Seth

Publication year - 2019

Publication title -

indian journal of pathology and microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.217

H-Index - 31

eISSN - 0974-5130

pISSN - 0377-4929

DOI - 10.4103/ijpm.ijpm_726_17

Subject(s) - imatinib , fusion transcript , exon , breakpoint cluster region , chromosomal translocation , medicine , imatinib mesylate , fusion gene , breakpoint , biology , oncology , cancer research , gastroenterology , genetics , gene , receptor , myeloid leukemia

Philadelphia chromosome (Ph): Hallmark of CML is caused by reciprocal translocation between chromosomes 9 and 22 resulting in BCR-ABL fusion protein. Most commonly associated breakpoint with CML is M-bcr in exon 13 or exon 14, producing splice variant b2a2 or b3a2 respectively. The distribution of these transcripts and their influence on clinico-hematological parameters is variable. Impact of the fusion transcripts on treatment outcome in Imatinib treated CML patients is still a matter of debate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research